Newsletter Tool

Today’s Big News

Jun 23, 2025

Novo's injectable amycretin yet to hit weight loss plateau, suggesting Zepbound-beating potential

Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication

Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed

Otsuka pens $670M pact to point Harbour's preclinical T-cell engager toward autoimmune disease

Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock higher

Leap expands layoffs to cover 75% of employees, scraps only clinical trial to save cash

Vertex's remaining islet cell therapy reduces dangerously low blood sugar levels in phase 1/2 test

Corxel, Sciwind post GLP-1 data as China's obesity push gathers pace

Featured

Novo's injectable amycretin yet to hit weight loss plateau, suggesting Zepbound-beating potential

By Nick Paul Taylor

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the Danish drugmaker can improve on the data that triggered a jump in its share price early this year. However, the tolerability data raised questions about the strength of Novo’s hand.

Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication

By James Waldron

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up to 545 million euros ($626 million) from a licensing deal with Sanofi.

Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed

By James Waldron

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed.

The World Can’t Wait: Delivering on the Promise of Biopharma’s “Golden Age” Mina Makar, Senior Vice President, Global Cardiovascular, Renal and Metabolism, AstraZeneca

Otsuka pens $670M pact to point Harbour's preclinical T-cell engager toward autoimmune disease

By James Waldron

Aiming T-cell engagers at autoimmune diseases continues to be a red-hot dealmaking target, as evidenced by Otsuka Pharmaceutical’s decision to pay $47 million upfront for the ex-China rights to Harbour BioMed’s BCMAxCD3 bispecific candidate.

Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock higher

By Nick Paul Taylor

A combination featuring Exelixis’ zanzalintinib has beaten Bayer’s Stivarga in a phase 3 trial. The overall survival win moves Exelixis a step closer to its ambition of turning the oral tyrosine kinase inhibitor into a $5 billion-a-year product.

Leap expands layoffs to cover 75% of employees, scraps only clinical trial to save cash

By James Waldron

Leap Therapeutics is expanding its layoff plans to encompass three-quarters of its staff while scrapping its sole clinical trial.

Vertex's remaining islet cell therapy reduces dangerously low blood sugar levels in phase 1/2 test

By James Waldron

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet cell therapy appears to be paying off so far.

Corxel, Sciwind post GLP-1 data as China's obesity push gathers pace

By Nick Paul Taylor

The 85th American Diabetes Association Scientific Sessions have shown the depth of China’s play for the GLP-1 market, with Corxel Pharmaceuticals and Sciwind Biosciences among the companies to share data at the event.

Lilly eyes global approval filings as once-weekly insulin candidate takes clinical victory lap

By Fraiser Kansteiner

Lilly provided a comprehensive look at positive results from a group of studies that assessed the company's once-a-week insulin candidate efsitora in multiple Type 2 diabetes patient populations. Lilly says it plans to submit its efsitora package to global regulators by the end of the year.

Roche's bispecific-ADC combo keeps cancer at bay in 2nd shot at 2nd-line large B-cell lymphoma

By Angus Liu

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates—in a Lunsumio-Polivy regimen in large B-cell lymphoma.

Insurers pledge to smooth out the prior authorization process

By Paige Minemyer

Insurers large and small from across the country have announced a series of commitments they're making to reform one of the biggest pain points in the patient journey: prior authorization.

Illumina picks up proteomics developer SomaLogic from Standard BioTools for $425M

By Conor Hale

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business.

Fierce podcasts

Don’t miss an episode

AbbVie, ADCs and the future of cancer care

This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates.

Inside Fierce Medtech's Fierce 15

A bold bet on sharing real-time patient data

Resources

Executive Summary

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.